Gluckman CR, Metz DC. Gastric neuroendocrine tumors (Carcinoids). Curr Gastroenterol Rep. 2019. https://doi.org/10.1007/s11894-019-0684-7.

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017. https://doi.org/10.1001/jamaoncol.2017.0589.

Tsikitis VL, Wertheim BC, Guerrero MA. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer. 2012. https://doi.org/10.7150/jca.4502.

Kulke MH, Shah MH, Benson AB 3rd, Bergsland E, Berlin JD, Blaszkowsky LS, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw. 2015. https://doi.org/10.6004/jnccn.2015.0011.

Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009. https://doi.org/10.1159/000182196.

Shi H, Jiang Y, Cao H, Zhu H, Chen B, Ji W. Nomogram Based on Systemic Immune-Inflammation Index to Predict Overall Survival in Gastric Cancer Patients. Dis Markers. 2018. https://doi.org/10.1155/2018/1787424.

Zhang X, Hu D, Lin X, Zhang H, Xia Y, Lin J, et al. Prognostic Value of an Inflammation-Related Index in 6,865 Chinese Patients With Postoperative Digestive Tract Cancers: The FIESTA Study. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00427.

De Giorgi U, Procopio G, Giannarelli D, Sabbatini R, Bearz A, Buti S, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-18-3661.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017. https://doi.org/10.1016/j.lungcan.2017.07.024.

Kim NY, Chun DH, Kim SY, Kim NK, Baik SH, Hong JH, et al. Prognostic value of systemic inflammatory indices, NLR, PLR, and MPV, for predicting 1-year survival of patients undergoing cytoreductive surgery with HIPEC. J Clin Med. 2019. https://doi.org/10.3390/jcm8050589.

Chua TC, Chong CH, Liauw W, Zhao J, Morris DL. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg. 2012. https://doi.org/10.1097/SLA.0b013e3182602ad2.

Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2017. https://doi.org/10.1097/SLA.0000000000001988.

Pozza A, Pauletti B, Scarpa M, Ruffolo C, Bassi N, Massani M. Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with midgut neuroendocrine tumors undergoing resective surgery. Int J Color Dis. 2019. https://doi.org/10.1007/s00384-019-03356-5.

Zhou W, Kuang T, Han X, Chen W, Xu X, Lou W, et al. Prognostic role of lymphocyte-to-monocyte ratio in pancreatic neuroendocrine neoplasms. Endocr Connect. 2020. https://doi.org/10.1530/EC-19-0541.

Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, et al. A novel predictive model based on preoperative blood neutrophil-to-lymphocyte ratio for survival prognosis in patients with gastric neuroendocrine neoplasms. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.9805.

Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, et al. Nomogram based on tumor-associated neutrophil-to-lymphocyte ratio to predict survival of patients with gastric neuroendocrine neoplasms. World J Gastroenterol. 2017. https://doi.org/10.3748/wjg.v23.i47.8376.

Kroenke CH, Neugebauer R, Meyerhardt J, Prado CM, Weltzien E, Kwan ML, et al. Analysis of body mass index and mortality in patients with colorectal cancer using causal diagrams. JAMA Oncol. 2016. https://doi.org/10.1001/jamaoncol.2016.0732.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2016.66.7311.

Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS Study. JAMA Oncol. 2017. https://doi.org/10.1001/jamaoncol.2017.2319.

Feola T, Puliani G, Sesti F, Modica R, Centello R, Minotta R, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Investig. 2022. https://doi.org/10.1007/s40618-021-01715-0.

Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012. https://doi.org/10.1136/gutjnl-2011-300831.

Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006. https://doi.org/10.1007/s00428-006-0250-1.

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018. https://doi.org/10.1038/s41379-018-0110-y.

Division of Digestive Diseases CSoP, Chinese Consensus on the Pathological Diagnosis of G, Pancreatic Neuroendocrine Neoplasms Experts G. [Chinese consensus on the pathological diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasms (2020)]. Zhonghua Bing Li Xue Za Zhi. 2021. https://doi.org/10.3760/cma.j.cn112151-20200805-00623.

Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000. https://doi.org/10.1056/NEJM200012213432501.

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008. https://doi.org/10.1200/JCO.2007.15.4377.

Burkitt MD, Pritchard DM. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther. 2006. https://doi.org/10.1111/j.1365-2036.2006.03130.x.

Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg. 1999. https://doi.org/10.1097/00000658-199906000-00008.

Zhou B, Deng J, Chen L, Zheng S. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2017. https://doi.org/10.1038/s41598-017-17885-y.

Chen S, Guo J, Feng C, Ke Z, Chen L, Pan Y. The preoperative platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio: which is better as a prognostic factor in oral squamous cell carcinoma? Ther Adv Med Oncol. 2016. https://doi.org/10.1177/1758834016638019.

Song W, Tian C, Wang K, Zhang RJ, Zou SB. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: a systematic review and meta-analysis. PLoS One. 2017. https://doi.org/10.1371/journal.pone.0178762.

Xu Z, Xu W, Cheng H, Shen W, Ying J, Cheng F, et al. The prognostic role of the platelet-lymphocytes ratio in gastric cancer: a meta-analysis. PLoS One. 2016. https://doi.org/10.1371/journal.pone.0163719.

Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999. https://pubmed.ncbi.nlm.nih.gov/10096562/.

Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta. 2011. https://doi.org/10.1016/j.bbcan.2010.12.001.

Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004. https://doi.org/10.1016/j.immuni.2004.07.017.

Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017. https://doi.org/10.3322/caac.21405.

Merry AH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut. 2007. https://doi.org/10.1136/gut.2006.116665.

Tran GD, Sun XD, Abnet CC, Fan JH, Dawsey SM, Dong ZW, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2005. https://doi.org/10.1002/ijc.20616.

Barrea L, Muscogiuri G, Modica R, Altieri B, Pugliese G, Minotta R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne). 2021. https://doi.org/10.3389/fendo.2021.649496.

Muttillo EM, Mazzarella G, Picardi B, Rossi S, Cinelli L, Diana M, et al. Treatment strategies for neuroendocrine liver metastases: a systematic review. HPB (Oxford). 2022. https://doi.org/10.1016/j.hpb.2022.06.009.